Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-02
2010-10-19
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254050, C514S318000, C514S326000, C514S403000, C544S364000, C544S371000, C546S211000, C548S364100, C548S369400
Reexamination Certificate
active
07816361
ABSTRACT:
Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R1and R2independently represent H, or C1-C6alkyl; R3represents H; F; CI; Br, —NO2; —CN; C1-C6alkyl optionally substituted by F or CI; or C1-C6alkoxy optionally substituted by F; R4represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6or —NHC(═S)NR7R6wherein R6represents H, or a radical of formula -(Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12alkylene, or C2-C12alkenylene, or C2-C12alkynylene radical or a divalent C3-C12carbocyclic radical, any of which radicals may be interrupted by one or more —O—, —S— or —N(R8)— radicals wherein R8represents H or C1-C4alkyl, C3-C4alkenyl, C3-C4alkynyl, or C3-C6cycloalkyl, and Q represents H; —CF3; —OH; —SH; —NR8R8wherein each R8may be the same or different, or form a ring when taken together with the nitrogen to which they are attached; an ester group; or an optionally substituted aryl, aryloxy, cycloalkyl, cycloalkenyl or heterocyclic group; and R7represents H or C1-C6alkyl; or when taken together with the atom or atoms to which they are attached R6and R7form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z)n-(Alk)- or -(Alk)-(Z)n- wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R6and n is 0 or 1.
REFERENCES:
patent: 3576637 (1971-04-01), Suga et al.
patent: 4591589 (1986-05-01), Gasc et al.
patent: 5061705 (1991-10-01), Wuest et al.
patent: 7276505 (2007-10-01), Matthews
patent: 0 255 892 (1988-02-01), None
patent: 0 269 030 (1988-06-01), None
patent: 629 412 (1949-09-01), None
patent: 45 026736 (1970-09-01), None
patent: 97/34893 (1997-09-01), None
patent: 99/00391 (1999-01-01), None
patent: WO 03/004495 (2003-01-01), None
patent: 2004/048378 (2004-06-01), None
patent: 2004/055014 (2004-07-01), None
patent: 2004/081011 (2004-09-01), None
Picciola G et al: “Heterocyclic compounds with potential anti inflammatory activity containing 4-aminophenylalkanoic acid moieties. V. 2, 4-Dihydro-3H-pyrazol-3-one derivatives” Farmaco Edizione Scientifica., vol. 39, No. 4, 1984, pp. 371-378, XP009043142, Itsocieta Chimica Italiana, Pavia tables I, II compound 18902.
Database Beilstein 1992, XP002315401, Database accession No. 697617 (CNR) BRN 343115, 325012, 361725, 361896 & J. Prakt. Chem., vol. 2-121, 1929, p. 201.
Byun J-W et al “Preparation of polymer-bound pyrazolone active esters for combinatorial chemistry” Tetrahedron Letters., vol. 44, Oct. 27, 2003, pp. 8063-8067, XP004461054 Nlelsevier Science Publishers, Amsterdam.
Database Beilstein 1993, XP002315402, Database accession No. 695619 (CNR) BRN 695619, 312421 & Justus Liebigs Ann. Chem., vol. 373, 1910, p. 167.
Database Caplus Chemical Abstracts Service, Columbus, Ohio, US: 1971, XP002315403, Database accession No. 74:87973 (DN) RN 21749-59-7.
Appel & Brossart, “Development of Novel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions,” Endocrin. Metab. Immune Disord. Drug Targets No. 7, pp. 93-97, 2007.
Brumeanu et al., “Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors,” Clin. Immunol. vol. 119, pp. 1-12, 2006.
Chitale & Moots, “Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis,” Expert. Opin. Biol. Ther., vol. 8, pp. 115-122, 2008.
Choy, “T Cells in Psoriatic Arthritis,” Curr. Rheumatol. Rep. vol. 6, pp. 437-441, 2007.
Cope et al., “The central role of T cells in rheumatoid arthritis,” Clin. Exp. Rheumatol., vol. 25, pp. S4-S11, 2007.
Dubey et al., “Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate Naïve CD4 T Cell Activation but Both Are Required for Optimum Response,” J Immunol., vol. 155, pp. 45-57, 1995.
Gimmi et al., “Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation,” Immunology, vol. 90, pp. 6586-6590, Jul. 1993.
Kristensen et al., “The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review,” Scand. J. Rheumatol., vol. 36, pp. 411-417, 2007.
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med. vol. 173, pp. 721-730, Mar. 1991.
Mallone & Endert, “T Cells in the Pathogenesis of Type 1 Diabetes,” Curr. Diab. Rep., vol. 8, pp. 101-106, 2008.
Suresh et al., “Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory,” The Journal of Immunology, vol 167: pp. 5565-5573, 2001.
Weiss et al., .“Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory,” Neuroimmunol. vol. 191, pp. 79-85, 2007.
Medigene Press Release, “RhuDex(TM) Clinical Development to Continue Following Feedback from Regulatory Authorities,” Oct. 5, 2009.
Collins et al., “The interaction properties of costimulatory molecules revisited,” Immunity, vol. 17, pp. 201-210, 2002.
Lenschow et al., “CD28/B7 system of T cell costimulation,” Annu. Rev. Immunol., vol. 14, pp. 233-258, 1996.
Huxley et al., “High-affinity small molecule inhibitors of T cell costimulation,” Chem. Biol., vol. 11, pp. 1651-1658, 2004.
Salomon et al., B7/CD28 costimation cells is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes; Immunity, vol. 12, pp. 431-440, 2000.
West, “Solid state chemistry and its applications,” Wiley & Sons, New York, book Chapter 10, pp. 358-359, 1988.
Griesser, “The Importance of Solvates,” Polymorphism in the Pharmazuetical Industry, Chapter 8, pp. 211-230, 2006.
Strieth et al., “Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin,” Clin Cancer Res., vol. 14, No. 14, pp. 4603-4611, 2008.
Lukes et al., “Oral feeding with pig peripheral lymphocytes decreases the xenogeneic delayed type hypersensitivity reaction in galactosyltransferase knockout mice,” Abstract, Transplant Proc., vol. 37, No. 8, pp. 3327-3331, 2005.
Strieth et al., “Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes,” Int J Cancer, vol. 122, No. 2, pp. 452-460, 2008.
Ames & Bull, “Preparation of cinnoline-3, 4-dicarbonitrile and -dicarboxylic acid,” Tetrahedron, vol. 37, No. 14, pp. 2489-2491, 1981.
Banner & Witcoff , Ltd.
Medigene Limited
Saeed Kamal A
LandOfFree
Immuno inhibitory pyrazolone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immuno inhibitory pyrazolone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immuno inhibitory pyrazolone compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171573